Business Context and Reporting Period
The filing is Brooks Automation, Inc.’s unaudited Form 10-Q for the quarter ended December 31, 2017, although the request identifies the company as Azenta, Inc. The company reported two segments: Brooks Semiconductor Solutions Group and Brooks Life Sciences. It provides automation and cryogenic solutions for semiconductor equipment and life sciences sample management markets.
The quarter reflects the October 2017 acquisition of 4titude Limited, a U.K. manufacturer of scientific consumables, for approximately $65.2 million net of cash acquired.
Financial Performance and Liquidity
| Metric | Q1 FY2018 | Q1 FY2017 | Change |
|---|---|---|---|
| Total revenue | $189.3 million | $160.0 million | +18% |
| Gross profit | $75.2 million | $56.9 million | +$18.3 million |
| Gross margin | 39.7% | 35.6% | +4.1 percentage points |
| Operating income | $20.8 million | $13.2 million | +$7.7 million |
| Net income | $16.5 million | $13.9 million | +19% |
| Diluted EPS | $0.23 | $0.20 | +$0.03 |
| Operating cash flow | $3.2 million | $18.7 million | -$15.5 million |
Semiconductor Solutions revenue increased 12% to $141.9 million, while Life Sciences revenue increased 42% to $47.4 million. Life Sciences growth included $6.4 million from acquisitions and $7.7 million of internal growth. One semiconductor customer represented approximately 11% of consolidated revenue in both periods.
Cash, cash equivalents and marketable securities totaled $231.9 million at December 31, 2017, compared with $104.3 million at September 30, 2017. Cash and cash equivalents were $202.3 million. The quarter-end balance benefited primarily from $197.6 million of term-loan proceeds, partially offset by $65.1 million of acquisition spending, $26.9 million of marketable-securities purchases, $7.1 million of dividends and $2.7 million of capital expenditures.
The company had $200.0 million of outstanding senior secured term-loan principal, net of $2.7 million of deferred financing costs, with maturity in October 2024. The weighted average stated interest rate was approximately 4%. Approximately $51.1 million was available under a $75.0 million revolving credit facility, with no revolver borrowings outstanding. The company was in compliance with applicable debt covenants.
Material Changes Versus the Prior Comparable Period
- Revenue growth occurred in both reporting segments, supported by higher semiconductor product and service demand and increased Life Sciences activity.
- Gross margin improved primarily from favorable mix, volume leverage, lower material and service costs, and foreign-exchange benefits in Semiconductor Solutions.
- Life Sciences gross margin declined to 33.2% from 34.4%, mainly due to higher production costs and $1.2 million of acquisition-related inventory step-up charges.
- Research and development expense increased to $13.2 million from $10.8 million, and selling, general and administrative expense increased to $41.2 million from $32.0 million.
- There were no restructuring charges in Q1 FY2018 versus $1.0 million in Q1 FY2017.
- Interest expense increased to $2.2 million from $0.1 million following the new term loan. The prior period included a $1.8 million gain on settlement of an equity-method investment, which did not recur.
- Operating cash flow declined because of working-capital uses, including higher receivables and inventories and payments of accrued compensation.
Guidance, Outlook, Risks and Unusual Items
Management stated that existing cash, marketable securities, available credit and expected operating cash flows should fund working capital, capital expenditures, debt service and planned activities for the next twelve months. No specific quantitative revenue or earnings guidance was provided in the filing.
- Semiconductor demand is cyclical and may fluctuate significantly from quarter to quarter.
- The term loan has variable interest rates; management estimated that a 100-basis-point rate change would have changed quarterly interest expense by approximately $0.5 million.
- Foreign-currency losses were $2.0 million versus $0.5 million in the prior-year quarter. A hypothetical 10% currency move was estimated to affect quarterly net income by approximately $0.6 million.
- The company estimated accumulated foreign earnings of approximately $120 million for purposes of the Tax Cuts and Jobs Act toll-charge analysis, but had not recorded a toll-charge provision because available tax attributes and valuation allowances were expected to offset the inclusion. The estimate remained provisional under SAB 118.
- The company had $128.6 million of non-cancellable inventory purchase commitments and approximately $3.5 million of letters of credit outstanding.
- Legal proceedings arose in the ordinary course of business; management did not expect them to have a material adverse effect, but noted that outcomes remain unpredictable.
- The company expected future adoption of new lease, credit-loss and revenue-recognition standards. Revenue recognition changes could affect the timing of recognition for portions of Life Sciences revenue and license arrangements.
- A $0.10-per-share dividend was declared on January 31, 2018, payable March 23, 2018.
Investor Verification Items
- Confirm the filing entity: the provided filing is for Brooks Automation, Inc., not an entity identified in the request as Azenta, Inc.
- Reconcile the $127.6 million increase in cash, cash equivalents and marketable securities with term-loan proceeds, acquisition payments, securities purchases and operating cash flow.
- Assess the sustainability of the 39.7% gross margin, particularly the Semiconductor Solutions improvement and Life Sciences acquisition-related charges.
- Review the 4titude purchase-price allocation, goodwill of approximately $38.0 million and preliminary valuation assumptions.
- Evaluate variable-rate debt exposure, required amortization and the excess-cash-flow repayment requirement beginning December 31, 2018.
- Monitor working-capital conversion because operating cash flow materially underperformed net income in the quarter.
- Track provisional Tax Reform accounting, deferred-tax valuation allowances and potential foreign withholding or state-tax costs.